3 recent notable approvals of medical AI

Dave Pearson | | Health Exec | Economics
Green Light

Along with AI, this ongoing list includes regulatory clearances of virtual and augmented reality, 3D printing and other emerging technologies targeted for healthcare.

1. DiA Imaging Analysis (Be’er Sheva, Israel, Oct. 29)—FDA 510(k) clearance for AI selection of optimal echocardiogram views. Product: LVivo Seamless

2. IQ-AI (Jersey, Channel Islands, Nov. 4)—FDA 510(k) clearance for software that uses AI to process CT scans for virtual liver biopsy of patients with chronic liver disease. Product: Liver Surface Nodularity/LSN

3. SenseTime (Abu Dhabi, UAI, Nov. 4)—CE certification for AI interpretation of CT scans with suspected lung diseases, including COVID-19. Product: SenseCare-Lung Pro

To see the previous entry in this series, click here.

Dave Pearson
Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Related Content

Cardiologist sues health system over gender discrimination, unequal pay and hostile treatment
FTC, DOJ and HHS release report warning of private equity consolidation in healthcare
Q&A: Vulnerable patients hit hardest by anesthesia reimbursement cuts
Momentum continues for renal denervation as CMS considers national Medicare coverage
Johnson & Johnson buys depression drug and its manufacturer for $15B
UnitedHealth, Amedisys ask federal judge to dismiss DOJ lawsuit blocking $3.3B merger

Around the web

AI in Healthcare
Nat’l Academy of Medicine sets ‘priorities for action’ as healthcare mulls next moves with AI

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

Cardiovascular Business
Biden chooses semaglutide for next round of Medicare price negotiations—Trump gets final say

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

AI in Healthcare
4 ways HHS plans to help shape a national strategy for healthcare AI

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.